Higher serum uric acid translates to greater CV disease burden in chronic coronary syndromes
Among patients with chronic coronary syndromes, those with higher serum uric acid (SUA) levels are more likely to have major adverse cardiovascular (CV) events (MACE) and worse related quality of life (QoL), as reported in a study.
The study used data from a nationwide, prospective registry and included 5,070 consecutive chronic coronary syndromes patients, among whom 2,394 (47.2 percent) had available data on SUA levels. Outcomes assessed included MACE and QoL, a composite of CV death and hospitalization for myocardial infarction, heart failure (HF), angina, or revascularization over 1 year of follow-up.
SUA levels at baseline were in the low tertile (4.3 [3.7–4.7] mg/dL) among 860 patients, middle tertile (5.6 [5.3–5.9] mg/dL) among 739, and high tertile (7.1 [6.7–7.9] mg/dL) among 795.
The 1-year incidence of MACE was the highest among patients in the high SUA tertile (6.8 percent), followed by those in the middle and low tertiles (4.1 percent and 3.7 percent, respectively; p=0.005 for low vs high tertile).
Furthermore, patients in the high vs low tertile of SUA had a markedly higher rate of CV mortality (1.4 percent vs 0.4 percent; p=0.05) and hospital admission for HF (2.8 percent vs 1.6 percent; p=0.03).
However, multivariable Cox analysis showed that hyperuricaemia was not predictive of MACE (hazard ratio, 1.27, 95 percent confidence interval, 0.81–2.00; p=0.3).